The Effect of Methylphenidate on Prefrontal Cognitive Functioning, Inattention, and Hyperactivity in Velocardiofacial Syndrome
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Methylphenidate (MPH) is commonly used to treat attention-deficit/hyperactivity disorder (ADHD) in all children, including those with velocardiofacial syndrome (VCFS). Yet concerns have been raised regarding its safety and efficacy in VCFS. The goal of this study was to examine the safety and efficacy of MPH in children with VCFS. METHODS: Thirty-four children and adolescents with VCFS and ADHD participated in a randomized, controlled trial with a 2:1 ratio of MPH versus placebo. All subjects underwent a cardiological evaluation before and after MPH administration. The primary outcome measure was prefrontal cognitive performance following a single dose of MPH or placebo. A follow-up assessment was conducted after a 6-month treatment with MPH. RESULTS: Compared with placebo, single MPH administration was associated with a more robust improvement in prefrontal cognitive performance, including achievements in the Hearts and Flowers executive function task and the visual continuous performance task. After 6 months of treatment, a 40% reduction in severity of ADHD symptoms was reported by parents on the Revised Conners Rating Scale. All subjects treated with MPH reported at least one side effect, but it did not necessitate discontinuation of treatment. MPH induced an increase in heart rate and blood pressure that was usually minor, but was clinically significant in two cases. No differences in response to MPH were observed between catechol-O-methyltransferase Met versus Val carriers. CONCLUSION: The use of MPH in children with VCFS appears to be effective and relatively safe. A comprehensive cardiovascular evaluation for children with VCFS before and during stimulant treatment is recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Willcutt, E. G., Doyle, A. E., Nigg, J. T., Faraone, S. V., & Pennington, B. F. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.02.006 · Cited by 3,568
Davidson, M. C., Amso, D., Anderson, L. C., & Diamond, A. (2006) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2006.02.006 · Cited by 2,226
Self-citationPreschool Program Improves Cognitive Control
Diamond, A., Barnett, W. S., Thomas, J., & Munro, S. (2007) · Science · doi:10.1126/science.1151148 · Cited by 2,025 · cited 3×
“The task has three levels of difficulty: The congruent, incongruent, and mixed conditions, as has been previously described (Diamond et al. 2007; Kerns 1998; Petrides and Milner 1982; Davidson et al. 2006).”
Self-citationGenetic and neurochemical modulation of prefrontal cognitive functions in children
Diamond, A., Briand, L., Fossella, J., & Gehlbach, L. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.125 · Cited by 381 · cited 2×
“The task has three levels of difficulties—6, 8, and 12 lines of drawings (Collins et al. 1998; Diamond et al. 1997, 2004).”
Self-citationADHD Drugs and Cardiovascular Risk
Nissen, S. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068049 · Cited by 331
Stimulant treatment over five years: adherence, effectiveness, and adverse effects
Charach, A., Ickowicz, A., & Schachar, R. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200405000-00009 · Cited by 315
Vetter, V. L., Elia, J., Erickson, C., Berger, S., Blum, N., Uzark, K., & Webb, C. L. (2008) · Circulation · doi:10.1161/circulationaha.107.189473 · Cited by 296
Green, T., Gothelf, D., Glaser, B., Debbane, M., Frisch, A., Kotler, M., Weizman, A., & Eliez, S. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181b76683 · Cited by 289 · cited 8×
“As noted by previous studies, the depressive symptoms may reflect a predisposition of children with VCFS to develop depressive disorders (Green et al. 2009; Jolin et al. 2009).”
InfluentialSelf-citationA controlled trial of stimulant medication in children with the fragile X syndrome
Hagerman, R. J., Murphy, M. A., & Wittenberger, M. D. (1988) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320300138 · Cited by 158 · cited 2×
“On VCFS, there is only one 4-week open label study demonstrating MPH effectiveness for ADHD symptoms (Gothelf et al. 2003), and on fragile X syndrome, there is one controlled trial demonstrating a 66% response rate to MPH (Hagerman et al. 1988).”
Cardiovascular Responses of Hyperactive Children to Methylphenidate
Ballard, J. E. (1976) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1976.03270260026021 · Cited by 72 · cited 1×
“Following single MPH administration, we found a minimal increase in mean heart rate and diastolic blood pressure, which is in line with cardiovascular changes occurring in non-VCFS children (Ballard et al. 1976).”
Cited by
Schneider, M., Debbané, M., Bassett, A. S., Chow, E. W. C., Fung, W. L. A., van den Bree, M. B. M., Owen, M., Murphy, K. C., Niarchou, M., Kates, W. R., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070864 · Cited by 779
“2 deletion syndrome (43), despite official warnings by health authorities against its use in individuals with cardiac anomalies.”
BackgroundResultSelf-citationMethylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Storebø, O. J., Ramstad, E., Krogh, H. B., Nilausen, T. D., Skoog, M., Holmskov, M., Rosendal, S., Groth, C., Magnusson, F. L., Moreira-Maia, C. R., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009885.pub2 · Cited by 347
Storebø, O. J., Pedersen, N., Ramstad, E., Kielsholm, M. L., Nielsen, S. S., Krogh, H. B., Moreira-Maia, C. R., Magnusson, F. L., Holmskov, M., Gerner, T., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012069.pub2 · Cited by 321
Storebø, O. J., Krogh, H. B., Ramstad, E., Moreira-Maia, C. R., Holmskov, M., Skoog, M., Nilausen, T. D., Magnusson, F. L., Zwi, M., Gillies, D., et al. (2015) · BMJ · doi:10.1136/bmj.h5203 · Cited by 209
Ledochowski, J., Andrade, B. F., & Toplak, M. E. (2019) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2019.1567694 · Cited by 16
“Medication is often prescribed to ameliorate the symptoms of ADHD and has been shown to have favorable effects on EF (Brown et al., 2011; Green et al., 2011; Snyder, Maruff, Pietrzak, Cromer, & Snyder, 2008).”
Background
Metadata
- Authors
- Green, T., Weinberger, R., Diamond, A., Berant, M., Hirschfeld, L., Frisch, A., Zarchi, O., Weizman, A., & Gothelf, D.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2011-12
- Volume
- 21
- Issue
- 6
- Pages
- 589-595
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2015430685
- Cited by
- 46
- References
- 11
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of Methylphenidate on Prefrontal Cognitive Functioning, Inattention, and Hyperactivity in Velocardiofacial Syndrome. https://app.cochat.ai/papers/10.1089/cap.2011.0042
- The paper
- Green, T., Weinberger, R., Diamond, A., Berant, M., Hirschfeld, L., Frisch, A., Zarchi, O., Weizman, A., & Gothelf, D. (2011). The Effect of Methylphenidate on Prefrontal Cognitive Functioning, Inattention, and Hyperactivity in Velocardiofacial Syndrome. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2011.0042
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.